Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
We are a new centre (to be named) focused on Orthobiologics and Novel Cellular and Gene Therapies for Osteoarthritis. We have recently been funded through a generous gift of $6M from the Schroeder Foundation.
Led by Drs. Sowmya Viswanathan, Christopher Kim and Christian Veillette, this centre will combine scientific rigour and evidence-based medicine to advance research in four pillars:
1. An orthobiologics registry based on an AI approach that will inform a clinic of the future.
2a. A clinical cohort study to understand heterogeneity in patient responses to approved orthobiologic injection.
2b. A Health Canada-authorized clinical trial evaluating bone marrow aspirate, lipoaspirate against platelet-rich plasma.
3. A Health Canada-authorized clinical trial evaluating allogeneic fat-derived mesenchymal stromal cell therapy.
4. Next-generation technologies including gene therapies, 3D printed scaffolds, and pluripotent stem cell-derived immunotherapies to treat osteoarthritis, developed in
The ultimate beneficiaries will be people living with osteoarthritis who will be offered therapies that are tested, optimized, and customized for their particular profile. This will also secure the position of the Schroeder Arthritis Institute's Division of Orthopedics as a world leader for development of orthobiologics and cell-based therapies.
Pillar 1: Orthobiologics "Clinic of the Future"
Pillar 2a: Research cohort study – LEAP IN BIO (Longitudinal
Evaluation in the OsteoArthritis
Developing a biosignature that correlates with response to approved anti-inflammatory therapies.
This is a planned research cohort study involving 400 patients, and 1,600 patient visits over a three-year study. Patients will receive one of four Health Canada-approved orthobiologics (corticosteroid, hyaluronic acid, platelet rich plasma or autologous protein solution).
Pain treatment options in osteoarthritis (OA) have changed little over the years and significant challenges remain in effective symptomatic treatment of OA. Anti-inflammatory knee injections have become a treatment option and increasingly patients are inquiring about and requesting such injections.
However, treatment response is variable, and it is unclear who responds and does not respond to current intra-articular injections. Options of injections, as well as costs, continue to increase due to uncertainty in response; many approved injectates are not covered by public or private insurance and therefore present a significant clinical and economic challenge to patients and their providers with regards to one choosing the right patient for an injection and two the best injection for that patient.
The main goal of our study is to determine 1) who responds or does not respond to intra-articular anti-inflammatory injections and 2) why they respond the way they do. Our ultimate aim is to be able to predict patient response prior to injection and be able to develop and provide the right therapeutic to the right patient, at the right time, and at the right value.
Levels of baseline inflammation correlates with patient response to anti-inflammatory therapies. We further hypothesize that regional levels of inflammation are more correlative than systemic inflammation based on cohort study we completed that show strong inverse correlation of patient-reported outcome measures (PROMS) in knee OA patients with regional but not systemic levels of immune cells (Gómez-Aristizábal et al. 2019), and this is supported by other studies in the literature as well.
Stay tuned for enrollment into this cohort study.
Pillar 2b: ABLE OA (Autologous
Bone Marrow or
Liposapriate Evaluation against PRP in knee and shoulder
osteoarthritis patients): A clinical trial
This study will determine the efficacy of intra-articular injection of bone marrow aspirate concentrate (BMAC) or autologous lipoaspriate with platelet-rich plasma (PRP) against PRP in patients with knee or shoulder osteoarthritis. Efficacy will be measured as improvement in pain at 12 months after injection, relative to baseline and will be compared against PRP response rates. Drop out/failure rate (based on provided definition) will also be assessed in each group over the 12-month period, and specifically at 3, 6 and 12 months.
Secondarily functional joint-specific outcomes will be measured after BMAC, LA +PRP or PRP injections at baseline, 3, 6 and 12 months. Heterogeneity in cellular composition of BMA and LA will be assessed. As in the LEAP in BIO cohort study, heterogeneity in local and systemic immune cell profile and inflammatory profile will also be assessed.
AI approaches will be used to identify unique inflammatory, immune cell profiles agnostic to response status to determine whether these unbiased profiles correlate to or accurately predict response or in combination with other factors enhance our ability to predict response compared to clinically biased profiles. Health economics of receiving the different injections and cost of health care delivery will also be compared, post hoc.
Stay tuned for updates on the start and enrollment into this study.
Pillar 3: Bridging Health Canada-regulated clinical trial on allogenic adipose-derived mesenchymal stromal cells
We plan to conduct a bridging Health Canada authorized clinical trial on 40 knee OA patients using allogeneic adipose tissue-derived mesenchymal stromal cells (AD-MSCs). This trial is a bridge between our previously conducted autologous bone marrow-derived MSCs (Chahal et al. 2019) and autologous AD-MSCs trial conducted by collaborators in Europe (Pers et al., 2017). The bridging trial will assess safety and efficacy relative to baseline at 3, 6, 12 and 24 months using Knee Outcome and Osteoarthritis Scores (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) as PROMS, x-ray and MRI imaging and evaluation of local immune cell profile (synovial fluid at baseline and 3 months post-injection) and systemic inflammatory profile.
As a first step in this project, bioreactor(s) to scale up and produce Master Cell Banks (MCB) of allogenic AD-MSCs will be evaluated for MSC yield, potency, ease of use, cost and regulatory support. Data from these engineering runs will be used to support the regulatory Clinical Trial Application (CTA) filing.
Pillar 4: R&D into next-generation cellular/gene therapies
This last pillar is focused on forward-looking therapies being developed in the research lab of Dr. Viswanathan.
We are looking at several next-generation technologies in the pipeline including genetically engineered allogeneic MSCs, induced pluripotent stem cell (iPSC)-derived MSCs, and iPSC-derived and genetically engineered monocyte/macrophages, 3D printed synovial tissue/MSC-differentiated chondrocytes, etc.
These are largely research stage projects involving laboratory proof-of-concept experiments and animal studies and will pave the way for next-generation of OA cellular therapeutics which can be translated into the clinic.
A strong research arm will ensure a pipeline of new and emerging technologies that can be translated into clinical practice using the know-how we obtain from the other pillars, especially in terms of targeting appropriate patients and matching them with the most effective anti-inflammatory treatments.
Dr. Sowmya ViswanathanScientist, Schroeder Arthritis Institute/Krembil Research InstituteAssociate Professor, University of TorontoViswanathan Lab
Dr. Christian VeilletteHead, Division of Orthopedic Surgery
Dr. Chris KimOrthopedic Surgeon